Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger CCCH domain-containing protein 13 (ZC3H13)
- Target
- ZC3H13
- Molecular classification
- Zinc finger protein, RNA-binding protein, m6A RNA methylation regulator (component of m6A methyltransferase complex)
01
Overview
Zinc finger CCCH domain-containing protein 13 (ZC3H13) is an RNA-binding protein integral to the m6A methyltransferase complex that regulates N6-methyladenosine (m6A) modifications on mRNA, particularly at 3' untranslated regions. ZC3H13 helps retain complex members (WTAP, Virilizer, Hakai) in the nucleus, thereby controlling mRNA splicing, processing, and stem cell pluripotency. In cancer, notably acute myeloid leukemia, ZC3H13 promotes cell proliferation, enhances metabolic activity, and suppresses apoptosis and oxidative stress. Loss of ZC3H13 impairs m6A methylation globally and triggers differentiation in stem cells. The gene is conserved evolutionarily (with orthologs in Drosophila and plants) and associated with cancer and developmental disorders
- Other names
- ZC3H13KIAA0853DKFZp434D1812XioZinc finger CCCH domain-containing protein 13Flacc (in Drosophila ortholog)
02
Mechanism of action
Potential mechanisms for drugs targeting ZC3H13 would include inhibition or modulation of m6A RNA methylation and related pathways, affecting cell proliferation and differentiation
03
Biological functions
m6A methylation of mRNA (N6-methyladenosine modification)Regulator of mRNA processing and splicingStabilizes nuclear localization of the m6A writer complexControls stem cell pluripotency and self-renewalPromotes cell proliferation and metabolic reprogramming in cancer (particularly AML)Suppresses apoptosis and oxidative stress
04
Disease associations
Cancer (Acute myeloid leukemia, endometrial carcinoma, Wilms tumor)Developmental disorders (supported by murine and Drosophila knockout studies)
05
Safety considerations
Global inhibition of m6A methylation could affect stem cell maintenance and developmentMight disrupt normal RNA processing and have widespread effects in non-cancerous tissues
06
Interacting drugs
None directly listed in the search results or curated databases as of current literature. Research into m6A modulators may provide indirect candidates.
07
Biomarkers
High ZC3H13 expression (in AML bone marrow and cell lines; may correlate with survival outcomes)Loss of m6A methylation at 3' UTR regions of mRNA
Beyond the preview
Go deeper on Zinc finger CCCH domain-containing protein 13 (ZC3H13).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger CCCH domain-containing protein 13 (ZC3H13).